Mergers and acquisitions are more than just exits for private biotech companies. They are the primary mechanism for returning capital to venture capitalists and LPs, who then reinvest those funds back into the ecosystem, fueling the next generation of innovative startups.

VC Bob Nelsen argues that even if large pharma companies appropriate ideas or gain leverage over US biotech, their financial success is ultimately beneficial. Profitable pharma companies must deploy massive cash reserves, much of which flows back into the biotech ecosystem through M&A, funding the next generation.

Large pharmaceutical companies face losing up to 50% of their revenues by 2030 due to the largest patent expiration wave in history. To survive, they will be forced to acquire innovation from the biotechnology sector, fueling a sustained M&A cycle for years to come.

To achieve a 4% growth rate by 2031, large pharma firms need to acquire $69 billion in new sales. However, an analysis shows only 28 suitable public targets existed recently, and 10 have already been acquired in the last two years, creating a stark supply-demand imbalance for late-stage assets.

The biopharma M&A landscape is no longer dominated solely by Big Pharma. A new class of well-capitalized biotechs like Argenx and Vertex has emerged as active buyers. This increases competition for assets and provides more exit options for smaller companies, altering deal dynamics for everyone.

The biotech ecosystem is a continuous conveyor belt from seed funding to IPO, culminating in acquisition by large biopharma. The recent industry-wide stall wasn't a failure of science, but a halt in M&A activity that backed up the entire system.

Private biotech CEO Jake Beecroft argues that large pharma mergers harm innovation. They create R&D uncertainty lasting over 18 months, freeze capital that would otherwise go to partnerships, and ultimately remove a key potential acquirer or partner from the ecosystem.

M&A is often framed as a win, but it can be detrimental to patients. The acquisition of an aggressive, fast-moving biotech by a large pharma company can lead to slowed development timelines and more conservative regulatory strategies, ultimately delaying access to life-saving treatments.

While celebrated, the current wave of high-value acquisitions of promising companies like Sonora and Halda has a downside. It removes potential standalone success stories from the market, potentially weakening the public biotech index and depriving investors of future mid-cap growth engines.